PFKM and neoplasm: Hypoxia is proposed to afford a growth advantage to tumours partly mediated by the O-GlcNAc potentiation of the glycolytic enzyme, phosphofructokinase 1 (PFK1) at S529, thereby driving the pentose phosphate pathway in the generation of NADPH and GSH, which protects tumours from raised ROS levels [109].